Literature DB >> 20556411

Soluble CSF interleukin 2 receptor as indicator of neurosarcoidosis.

Hela-Felicitas Petereit1, Dirk Reske, Hayrettin Tumani, Sven Jarius, F Markus Leweke, Dirk Woitalla, Hans-Walter Pfister, Andrea Rubbert.   

Abstract

Neurosarcoidosis (NS) represents an important differential diagnosis of multiple sclerosis (MS). However, thus far no reliable laboratory marker of neurosarcoidosis exists. The objective of this study was to evaluate whether cerebrospinal fluid (CSF) levels of soluble interleukin 2 receptor (sIL2-R) distinguish NS and other inflammatory disorders of the central nervous system. For this purpose, 139 paired CSF and serum samples from 11 patients with NS, 21 with MS, 10 with CNS vasculitis, 22 with bacterial meningitis, 17 with viral meningitis/encephalitis, seven with neurotuberculosis, and 18 healthy donors were assessed for sIL2-R using an enzyme-linked immunosorbent assay. We found that sIL2-R CSF levels above 150 pg/ml identified untreated NS patients with an overall accuracy of 93% against a group of non-infectious CNS-diseases. Furthermore, an increase in sIL2-R in the CSF was associated with and preceded the outbreak of new neurological symptoms. In conclusion, these findings suggest that sIL2-R measurement in the CSF may be a valuable tool in the diagnosis and follow-up of patients with suspected and proven neurosarcoidosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20556411     DOI: 10.1007/s00415-010-5623-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis.

Authors:  N Keicho; K Kitamura; F Takaku; H Yotsumoto
Journal:  Chest       Date:  1990-11       Impact factor: 9.410

Review 2.  Diagnosis and management of neurosarcoidosis.

Authors:  F C Vinas; S Rengachary
Journal:  J Clin Neurosci       Date:  2001-11       Impact factor: 1.961

3.  Neurosarcoidosis. Clinical description of 7 cases with a proposal for a new diagnostic strategy.

Authors:  Sabrina Marangoni; Vincenza Argentiero; Bruno Tavolato
Journal:  J Neurol       Date:  2005-11-14       Impact factor: 4.849

4.  The prevalence of sarcoidosis in the autopsy material from a Swedish town.

Authors:  I Hägerstrand; F Linell
Journal:  Acta Med Scand Suppl       Date:  1964

5.  Cerebrospinal fluid angiotensin-converting enzyme for diagnosis of central nervous system sarcoidosis.

Authors:  Julie Khoury; Kay E Wellik; Bart M Demaerschalk; Dean M Wingerchuk
Journal:  Neurologist       Date:  2009-03       Impact factor: 1.398

6.  Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation.

Authors:  Jan C Grutters; Jean-Marc Fellrath; Leontine Mulder; Rob Janssen; Jules M M van den Bosch; Heleen van Velzen-Blad
Journal:  Chest       Date:  2003-07       Impact factor: 9.410

7.  Neurosarcoidosis: a study of 30 new cases.

Authors:  F G Joseph; N J Scolding
Journal:  J Neurol Neurosurg Psychiatry       Date:  2008-10-31       Impact factor: 10.154

8.  Soluble interleukin 2 receptors are released from activated human lymphoid cells in vitro.

Authors:  L A Rubin; C C Kurman; M E Fritz; W E Biddison; B Boutin; R Yarchoan; D L Nelson
Journal:  J Immunol       Date:  1985-11       Impact factor: 5.422

9.  Correlation of clinical and immunologic parameters of the inflammatory activity of pulmonary sarcoidosis.

Authors:  J Müller-Quernheim; S Pfeifer; J Strausz; R Ferlinz
Journal:  Am Rev Respir Dis       Date:  1991-12

10.  Central nervous system sarcoidosis--diagnosis and management.

Authors:  J P Zajicek; N J Scolding; O Foster; M Rovaris; J Evanson; I F Moseley; J W Scadding; E J Thompson; V Chamoun; D H Miller; W I McDonald; D Mitchell
Journal:  QJM       Date:  1999-02
View more
  11 in total

1.  Spinal cord sarcoidosis in Japan: utility of cerebrospinal fluid examination and nerve conduction study for diagnosis and prognosis prediction.

Authors:  Miwako Fujisawa; Michiaki Koga; Ryota Sato; Mariko Oishi; Yukio Takeshita; Takashi Kanda
Journal:  J Neurol       Date:  2022-04-17       Impact factor: 6.682

Review 2.  Sarcoidosis vs. Sarcoid-like reactions: The Two Sides of the same Coin?

Authors:  Georgi Tchernev; Claudio Tana; Cosima Schiavone; José-Carlos Cardoso; Julian Ananiev; Uwe Wollina
Journal:  Wien Med Wochenschr       Date:  2014-03-25

3.  Linkage of type I interferon activity and TNF-alpha levels in serum with sarcoidosis manifestations and ancestry.

Authors:  Nadera J Sweiss; Wei Zhang; Beverly S Franek; Silvia N Kariuki; David R Moller; Karen C Patterson; Peggy Bennett; Lakshmi R Girijala; Vaisak Nair; Robert P Baughman; Joe G N Garcia; Timothy B Niewold
Journal:  PLoS One       Date:  2011-12-14       Impact factor: 3.240

4.  Nemesis of neglected neurosarcoidosis.

Authors:  David B Clifford
Journal:  Ann Clin Transl Neurol       Date:  2015-09-17       Impact factor: 4.511

Review 5.  Clinical features, treatment and outcome in neurosarcoidosis: systematic review and meta-analysis.

Authors:  Daan Fritz; Diederik van de Beek; Matthijs C Brouwer
Journal:  BMC Neurol       Date:  2016-11-15       Impact factor: 2.474

6.  Application of the modified Zajicek criteria to diagnose probable spinal cord neurosarcoidosis.

Authors:  Ceris Ifan Owen; Farrah Jabeen; Anupam Bhattacharjee
Journal:  Clin Case Rep       Date:  2018-07-10

7.  Diagnostic markers for CNS lymphoma in blood and cerebrospinal fluid: a systematic review.

Authors:  Anouk van Westrhenen; Lisanne C A Smidt; Tatjana Seute; Stefan Nierkens; Abraham C J Stork; Monique C Minnema; Tom J Snijders
Journal:  Br J Haematol       Date:  2018-05-29       Impact factor: 6.998

8.  Interleukin-2 Receptor and Angiotensin-Converting Enzyme as Markers for Ocular Sarcoidosis.

Authors:  Enken Gundlach; Michael Marcus Hoffmann; Antje Prasse; Sonja Heinzelmann; Thomas Ness
Journal:  PLoS One       Date:  2016-01-22       Impact factor: 3.240

9.  Successful therapy with rituximab in three patients with probable neurosarcoidosis.

Authors:  Samis Zella; Janina Kneiphof; Aiden Haghikia; Ralf Gold; Dirk Woitalla; Jan Thöne
Journal:  Ther Adv Neurol Disord       Date:  2018-10-26       Impact factor: 6.570

Review 10.  [Current cerebrospinal fluid diagnostics for pathogen-related diseases].

Authors:  S D Süssmuth; J Brettschneider; A Spreer; M Wick; S Jesse; J Lewerenz; M Otto; H Tumani
Journal:  Nervenarzt       Date:  2013-02       Impact factor: 1.214

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.